SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 75 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 0.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $2,486,183 | -17.0% | 117,717 | 0.0% | 0.10% | -15.9% |
Q4 2022 | $2,995,898 | +175.6% | 117,717 | +108.4% | 0.11% | +162.8% |
Q2 2022 | $1,087,000 | +10.7% | 56,480 | 0.0% | 0.04% | +26.5% |
Q1 2022 | $982,000 | +30.4% | 56,480 | -60.6% | 0.03% | +9.7% |
Q1 2019 | $753,000 | -15.4% | 143,438 | -28.3% | 0.03% | -18.4% |
Q4 2018 | $890,000 | -44.9% | 200,000 | 0.0% | 0.04% | -35.6% |
Q3 2018 | $1,616,000 | +15.1% | 200,000 | 0.0% | 0.06% | +11.3% |
Q2 2018 | $1,404,000 | -50.7% | 200,000 | 0.0% | 0.05% | -52.3% |
Q1 2018 | $2,846,000 | +62.4% | 200,000 | 0.0% | 0.11% | +63.2% |
Q4 2017 | $1,752,000 | -25.1% | 200,000 | 0.0% | 0.07% | -19.0% |
Q3 2017 | $2,340,000 | -16.2% | 200,000 | 0.0% | 0.08% | -19.2% |
Q2 2017 | $2,794,000 | – | 200,000 | – | 0.10% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |